Article Information
History
- December 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Peter Richmond1,
- Lara Hatchuel2,
- Min Dong3,
- Brenda Ma3,
- Branda Hu3,
- Igor Smolenov3,
- Ping Li3,
- Peng Liang3,
- Htay Htay Han3,
- Joshua Liang3 and
- Ralf Clemens4,*
- 1Division of Paediatrics, University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute and Perth Children’s Hospital, Perth, Western Australia
- 2Linear Clinical Research, Nedlands, Western Australia
- 3Clover Biopharmaceuticals, Chengdu, China
- 4Global Research in Infectious Diseases (GRID), Rio de Janeiro, Brazil
- ↵*Corresponding author
Ralf Clemens, Global Research in Infectious Diseases (GRID), Rio de Janeiro, Brazil, e-mail: clemens.ralf{at}outlook.com
Posted December 04, 2020.
A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial
